Allogene replaces Zai Lab-bound Rafael Amado with Zachary Roberts

3 January 2023

CAR-T therapy company Allogene Therapeutics (Nasdaq: ALLO) has swiftly named its replacement for executive vice president of research and development Rafael Amado, who has resigned to join Sino-American firm Zai Lab (Nasdaq: ZLAB)."I am excited to work again with some of the pioneers of cell therapy"

Zachary Roberts will replace the departing Dr Amado, who leaves after more than three years with Allogene in a career that has also taken in Adaptimmune (Nasdaq: ADAP), GSK (LSE: GSK) and Amgen (Nasdaq: AMGN), to become Zai Lab's president, head of global oncology research and development.

Prior to joining Allogene, Dr Roberts was chief medical officer of Instil Bio (Nasdaq: TIL), where he led the development of both clinical and pre-clinical programs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK